Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
Hims & Hers forecasts 2026 revenue above estimates
Hims & Hers forecasts 2026 revenue above estimates
The New York Stock Exchange with a Hims & Hers Health, Inc banner is pictured as a person runs past in the Manhattan borough of New York City, New York, U.S., January 21, 2021. REUTERS/Carlo Allegri · Reuters
Reuters
Tue, February 24, 2026 at 6:19 AM GMT+9 1 min read
In this article:
HIMS
-0.77%
NVO
-16.43%
Feb 23 (Reuters) - Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for its personalized healthcare offerings.
Shares of the company are down 52% so far this year after its plan to launch a $49 compounded version of Novo Nordisk’s weight-loss pill Wegovy backfired due to swift backlash from U.S. authorities. Earlier this month, Hims said it planned to offer compounded copies of Novo’s new Wegovy pill at an introductory price of $49 per month.
The company then reversed course on its plans after the U.S. Food and Drug Administration said it would take action against manufacturers mixing ingredients to produce copies of GLP-1 drugs, referring it to the Department of Justice for potential violations of federal law.
The company forecast 2026 revenue to be in the range of $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion, as per data compiled by LSEG.
The company reported quarterly revenue of $617.8 million, an increase of 28% year-over-year, but below the analysts’ average estimate of $619.22 million.
(Reporting by Sneha S K in Bengaluru; Editing by Alan Barona)
Terms and Privacy Policy
Privacy Dashboard
More Info